公开(公告)号：US20220411522A1

公开(公告)日：2022-12-29

申请号：US17684238

申请日：2022-03-01

Applicant: GENMAB B.V.

Inventor： Frank BEURSKENS ,  Marije OVERDIJK ,  Rob DE JONG ,  David SATIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C12N15/62

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20190202926A1

公开(公告)日：2019-07-04

申请号：US15780285

申请日：2016-12-01

Applicant: GENMAB B.V.

Inventor： Frank BEURSKENS ,  Marije OVERDIJK ,  Rob DE JONG ,  David SATIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/30 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/73 ,  C07K2317/75 ,  C12N15/62

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.